AA amyloidosis: Pathogenesis and targeted therapy

Annual Review of Pathology: Mechanisms of Disease

Volumn 10, Issue , 2015, Pages 321-344

  Westermark, Gunilla T ^a   Fändrich, Marcus ^b   Westermark, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

acute phase; fibril; rheumatoid arthritis; serum amyloid A; strains; toxic oligomer

Indexed keywords

AMYLIN; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; ANTISENSE OLIGONUCLEOTIDE; CYTOSTATIC AGENT; DOXYCYCLINE; GELATINASE A; HEPARAN SULFATE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; PITTSBURGH COMPOUND B; POLYELECTROLYTE; PRION PROTEIN; PROTEIN AGGREGATE; PROTEIN PRECURSOR; PROTEOHEPARAN SULFATE; SERUM AMYLOID A; STROMELYSIN; TUMOR NECROSIS FACTOR; AMYLOID;

ABDOMINAL ADIPOSE TISSUE BIOPSY; ABDOMINAL FAT; AGING; ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; BETA SHEET; BIOPSY; BONE MARROW TRANSPLANTATION; CARBOXY TERMINAL SEQUENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRYSTAL; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENETIC RISK; HOMOZYGOSITY; HUMAN; IMMUNIZATION; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; LIVER TRANSPLANTATION; LYSOSOME; MACROPHAGE; MASS SPECTROMETRY; NONHUMAN; PATHOGENESIS; POINT MUTATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN SECONDARY STRUCTURE; TISSUE DISTRIBUTION; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

AMYLOID; AMYLOIDOSIS; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN STRUCTURE, SECONDARY; SERUM AMYLOID A PROTEIN;

EID: 84921923130     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-020712-163913     Document Type: Article

References (151)

1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, et al. 2012. Amyloid fibril protein nomenclature: 2012 recommendations from theNomenclatureCommittee of the International Society of Amyloidosis. Amyloid 19:167-70
2. Shirahama T, Cohen AS. 1967. High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol. 33:679-708
3. Sunde M, Blake CC. 1998. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q. Rev. Biophys. 31:1-39
4. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, et al. 2007. Atomic structures of amyloid cross-βspines reveal varied steric zippers. Nature 447:453-57
5. Sachse C, Fandrich M, Grigorieff N. 2008. Paired β-sheet structure of an Aβ(1-40) amyloid fibril revealed by electron microscopy. PNAS 105:7462-66
6. Schmidt M, Sachse C, Richter W, Xu C, Fandrich M, Grigorieff N. 2009. Comparison of Alzheimer Aβ(1-40) and Aβ(1-42) amyloid fibrils reveals similar protofilament structures. PNAS 106:19813-18
7. Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, Meier BH. 2008. Amyloid fibrils of the HET-s(218-289) prion form a βsolenoid with a triangular hydrophobic core. Science 319:1523-26
8. Eanes ED, Glenner GG. 1968. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16:673-77
9. Fandrich M. 2007. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell. Mol. Life Sci. 64:2066-78
10. Chiti F, Dobson CM. 2006. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75:333-66
11. Westermark P. 2005. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 272:5942-49
12. Kisilevsky R. 2000. Review: amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol. 130:99-108
13. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, et al. 2005. Raft lipids as common components of human extracellular amyloid fibrils. PNAS 102:6297-302
14. Pepys MB. 2006. Amyloidosis. Annu. Rev. Med. 57:223-41
15. Fowler DM, Koulov AV, Balch WE, Kelly JW. 2007. Functional amyloid-from bacteria to humans. Trends Biochem. Sci. 32:217-24
16. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. 2009. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 2009:959-91
17. Fandrich M. 2012. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J. Mol. Biol. 421:427-40
18. Azevedo EP, Pereira HM, Garratt RC, Kelly JW, Foguel D, Palhano FL. 2011. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-Aggregate during A25TTTR fibrillogenesis in cerebrospinal fluid. Biochemistry 50:11070-83
19. Lansbury Jr. PT. 1999. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. PNAS 96:3342-44
20. Ben-Zvi I, Livneh A. 2011. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat. Rev. Rheumatol. 7:105-12
21. Lane T, Loeffler JM, Rowczenio DM, Gilbertson JA, Bybee A, et al. 2013. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum. 65:1116-21
22. Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. 1998. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 5:262-65
23. Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, et al. 1995. A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-Amyloidosis. Hum. Mol. Genet. 4:1083-87
24. Moriguchi M, Terai C, Kaneko H, Koseki Y, Kajiyama H, et al. 2001. A novel single-nucleotide polymorphism at the 5-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum. 44:1266-72
25. Yamada T, Okuda Y, Takasugi K, Wang L, Marks D, et al. 2003. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid 10:7-11
26. Murphy CL, Wang S, Kestler DP, Stevens FA, Weiss DT, Solomon A. 2009. AA amyloidosis associated with a mutated serum amyloid A4 protein. Amyloid 16:84-88
27. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R. 1988. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem. J. 256:775-83
28. Noborn F, O'Callaghan P, Hermansson E, Zhang X, Ancsin JB, et al. 2011. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. PNAS 108:5584-89
29. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, et al. 2010. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468:93-97
30. Lindquist SL, Kelly JW. 2011. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb. Perspect. Biol. 3:a004507
31. Taylor RC, Dillin A. 2011. Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 3:a004440
32. David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, Kenyon C. 2010. Widespread protein aggregation as an inherent part of aging in C. Elegans. PLOS Biol. 8:e1000450
33. Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, et al. 2002. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 45:321-32
34. Zhao L, Buxbaum JN, Reixach N. 2013. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 52:1913-26
35. Jarrett JT, Lansbury PT. 1993. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 73:1055-58
36. Sachse C, Grigorieff N, Fandrich M. 2010. Nanoscale flexibility parameters of Alzheimer amyloid fibrils determined by electron cryo-microscopy. Angew. Chem. Int. Ed. Engl. 49:1321-23
37. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8:101-12
38. Hebda JA, Miranker AD. 2009. The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes. Annu. Rev. Biophys. 38:125-52
39. Bolognesi B, Kumita JR, Barros TP, Esbjorner EK, Luheshi LM, et al. 2010. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 20:735-40
40. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. 2004. Tissue damage in the amyloidoses: transthyretinmonomers and nonnative oligomers are themajor cytotoxic species in tissue culture. PNAS 101:2817-22
41. Smith AM, Jahn TR, Ashcroft AE, Radford SE. 2006. Direct observation of oligomeric species formed in the early stages of amyloid fibril formation using electrospray ionisation mass spectrometry. J. Mol. Biol. 364:9-19
42. Westermark P, Andersson A, Westermark GT. 2011. Islet amyloid polypeptide, islet amyloid and diabetes mellitus. Physiol. Rev. 91:795-826
43. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, et al. 2010. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?. Diabetologia 53:1046-56
44. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, et al. 2012. Atomic view of a toxic amyloid small oligomer. Science 335:1228-31
45. Wang Y, Srinivasan S, Ye Z, Javier Aguilera J, Lopez MM, Colon W. 2011. Serum amyloid A 2.2 refolds into a octameric oligomer that slowly converts to a more stable hexamer. Biochem. Biophys. Res. Commun. 407:725-29
46. Yu J, Zhu H, Guo JT, de Beer FC, Kindy MS. 2000. Expression of mouse apolipoprotein SAA1.1 in CE/J mice: isoform-specific effects on amyloidogenesis. Lab. Investig. 80:1797-806
47. Mori M, Tiang G, Higuchi K. 2014. AA amyloidosis-resistant CE/J mice have Saa1 and Saa2 genes that encode an identical SAA isoform. Amyloid 21:1-8
48. Senthilkumar S, Chang E, Jayakumar R. 2008. Diffusible amyloid oligomers trigger systemic amyloidosis in mice. Biochem. J. 415:207-15
49. Westermark P, Nilsson GT. 1984. Demonstration of amyloid protein A in old museum specimens. Arch. Pathol. Lab. Med. 108:217-19
50. Mutru O, Laakso M, Isomaki H, Koota K. 1985. Ten years mortality and causes of death in patients with rheumatoid arthritis. Br. Med. J. 290:1797-99
51. Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, et al. 2014. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod. Rheumatol. 24:137-43
52. Hazenberg BP, van Rijswijk MH. 2000. Where has secondary amyloid gone?. Ann. Rheum. Dis. 59:577-79
53. Immonen K, Finne P, Gr onhagen-Riska C, Pettersson T, Klaukka T, et al. 2011. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases-data from nationwide registries in Finland. Amyloid 18:25-28
54. McAdam KP, Raynes JG, Alpers MP, Westermark GT, Westermark P. 1996. Amyloidosis: a global problem common in Papua New Guinea. P.N.G. Med. J. 39:284-96
55. Bunker D, Gorevic P. 2012. AA amyloidosis: Mount Sinai experience 1997-2012. Mt. Sinai J. Med. 79:749-56
56. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. 1994. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1:119-37
57. Kisilevsky R, Manley PN. 2012. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 19:5-14
58. Yoshizaki K. 2011. Pathogenic role of IL-6 combined with TNF-αor IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases. Adv. Exp. Med. Biol. 691:141-50
59. Santiago P, Roig-Lopez JL, Santiago C, Garcia-Arraras JE. 2000. Serum amyloid A protein in an echinoderm: its primary structure and expression during intestinal regeneration in the sea cucumber Holothuria glaberrima. J. Exp. Zool. 288:335-44
60. Lu J, Yu Y, Zhu I, Cheng Y, Sun PD. 2014. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. PNAS 111:5189-94
61. Srinivasan S, Patke S, Wang Y, Ye Z, Litt J, et al. 2013. Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. J. Biol. Chem. 288:2744-55
62. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R. 1991. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J. Histochem. Cytochem. 39:1321-30
63. Noborn F, Ancsin JB, Ubhayasekera W, Kisilevsky R, Li JP. 2012. Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. J. Biol. Chem. 287:25669-77
64. Shirahama T, Cohen AS. 1975. Intralysosomal formation of amyloid fibrils. Am. J. Pathol. 81:101-16
65. Elimova E, Kisilevsky R, Ancsin JB. 2009. Heparan sulfate promotes the aggregation ofHDL-Associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch. FASEB J. 23:3436-48
66. Ishii W, Liepnieks JJ, Yamada T, Benson MD, Kluve-Beckerman B. 2013. Human SAA1-derived amyloid deposition in cell culture: a consistent model utilizing human peripheral blood mononuclear cells and serum-free medium. Amyloid 20:61-71
67. Lundmark K, Vahdat Shariatpanahi A, Westermark GT. 2013. Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis. PLOS ONE 8:e79104
68. Kennel SJ, Macy S, Wooliver C, Huang Y, Richey T, et al. 2014. Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. Amyloid 21:45-53
69. Kisilevsky R, Boudreau L. 1983. Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab. Investig. 48:53-59
70. Kluve-Beckerman B, Manaloor J, Liepnieks JJ. 2001. Binding, trafficking and accumulation of serum amyloid A in peritoneal macrophages. Scand. J. Immunol. 53:393-400
71. Yamada T, Liepnieks JJ, Kluve-Beckerman B, Benson MD. 1995. Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand. J. Immunol. 41:94-97
72. Chronopoulos S, Laird DW, Ali-Khan Z. 1994. Immunolocalization of serum amyloid A and AA amyloid in lysosomes in murine monocytoid cells: confocal and immunogold electron microscopic studies. J. Pathol. 173:361-69
73. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, R ocken C. 2001. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1,-2, and-3. Am. J. Pathol. 159:561-70
74. van der Hilst JC, Yamada T, Op den KampHJ, van der Meer JW, Drenth JP, Simon A. 2008. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology 47:1651-54
75. Nystr om SN, Westermark GT. 2012. AA-Amyloid is cleared by endogenous immunological mechanisms. Amyloid 19:138-45
76. Maury CP, Teppo AM. 1988. Antibodies to amyloid A protein in rheumatic diseases. Rheumatol. Int. 8:107-11
77. Magy N, Benson MD, Liepnieks JJ, Kluve-Beckerman B. 2007. Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid 14:51-63
78. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, et al. 2002. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295:851-55
79. Scheibel T, Lindquist SL. 2001. The role of conformational flexibility in prion propagation and maintenance for Sup35p. Nat. Struct. Biol. 8:958-62
80. Lundmark K, Westermark GT, Olsen A, Westermark P. 2005. Protein fibrils in nature can enhance AA amyloidosis in mice: cross-seeding as a disease mechanism. PNAS 102:6098-102
81. Westermark P, Lundmark K, Westermark GT. 2009. Fibrils from designed non-Amyloid-related synthetic peptides induce AA-Amyloidosis during inflammation in an animal model. PLOS ONE 4:e6041
82. Ranlov P. 1967. The adoptive transfer of experimental mouse amyloidosis by intravenous injections of spleen cell extracts from casein-Treated syngeneic donor mice. Acta Pathol. Microbiol. Scand. 70:321-35
83. Janigan DT, Druet RL. 1968. Experimental murine amyloidosis in X-irradiated recipients of spleen homogenates or serum from sensitized donors. Am. J. Pathol. 52:381-90
84. Hardt F. 1971. Transfer amyloidosis. Am. J. Pathol. 65:411-24
85. Gajdusek DC, Gibbs Jr. CJ., Alpers M. 1966. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 209:794-96
86. Johan K, Westermark G, Engstr om U, GustavssonA' , Hultman P, Westermark P. 1998. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. PNAS 95:2558-63
87. Lundmark K, Westermark GT, Nystr om S, Murphy CL, Solomon A, Westermark P. 2002. Transmissibility of systemic amyloidosis by a prion-like mechanism. PNAS 99:6979-84
88. Yan J, Fu X, Ge F, Zhang B, Yao J, et al. 2007. Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am. J. Pathol. 171:172-80
89. S orby R, Espenes A, Landsverk T, Westermark G. 2008. Rapid induction of experimental AA amyloidosis in mink by intravenous injection of amyloid enhancing factor. Amyloid 15:20-28
90. Murakami T, Naeem M, Inoshima Y, Yanai T, Goryo M, Ishiguro N. 2013. Experimental induction oral transmission of avian AA amyloidosis in vaccinated white hens. Amyloid 20:80-85
91. Zhang B, Une Y, Fu X, Yan J, Ge F, et al. 2008. Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. PNAS 105:7263-68
92. Cui D, Kawano H, Takahashi M, Hoshii Y, Setoguchi M, et al. 2002. Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. Pathol. Int. 52:40-45
93. Solomon A, Richey T, Murphy CL, Weiss DT, Wall JS, et al. 2007. Amyloidogenic potential of foie gras. PNAS 104:10998-1001
94. Yoshida T, Zhang P, Fu X, Higuchi K, Ikeda SI. 2009. Slaughtered aged cattle might be one dietary source exhibiting amyloid enhancing factor activity. Amyloid 16:25-31
95. Shirahama T, Cohen AS. 1980. Redistribution of amyloid deposits. Am. J. Pathol. 99:539-50
96. Enqvist S, Sletten K, Stevens FJ, Hellman U, Westermark P. 2007. Germ line origin and somatic mutations determine the target tissues in systemic AL-Amyloidosis. PLOS ONE 2:e981
97. Levin M, Franklin EC, Frangione B, Pras M. 1972. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J. Clin. Investig. 51:2773-76
98. Sletten K, Husby G. 1974. The complete amino-Acid sequence of non-immunoglobulin amyloid fibril protein AS in rheumatoid arthritis. Eur. J. Biochem. 41:117-25
99. Westermark P, Sletten K, Eriksson M. 1979. Morphologic and chemical variation of the kidney lesions in amyloidosis secondary to rheumatoid arthritis. Lab. Investig. 41:427-31
100. Westermark GT, Sletten K, Westermark P. 1983. Massive vascular AA-Amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand. J. Immunol. 30:605-13
101. Falck HM, T ornroth T, Wegelius O. 1983. Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin. Nephrol. 19:137-42
102. Westermark GT, Sletten K, Grubb A, Westermark P. 1990. AA-Amyloidosis: tissue component-specific association of various protein AA subspecies and evidence of a fourth SAA gene product. Am. J. Pathol. 137:377-83
103. Westermark GT, Westermark P, Sletten K. 1987. Amyloid fibril protein AA: characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab. Investig. 57:57-64
104. Tanaka M, Chien P, Naber N, Cooke RA, Weissmann JS. 2004. Conformational variations in an infectious protein determine prion strain differences. Nature 428:323-28
105. Wadsworth JDF, Joiner S, Linehan JM, Asante EA, Brandner S, Collinge J. 2008. The origin of the prion agent of kuru: molecular and biological strain typing. Philos. Trans. R. Soc. B 363:3747-53
106. Colby DW, Giles K, Legname G, Wille H, Baskakov IV, et al. 2009. Design and construction of diverse mammalian prion strains. PNAS 106:20417-22
107. Makarava N, Baskakov IV. 2008. The same primary structure of the prion protein yields two distinct self-propagating states. J. Biol. Chem. 283:15988-96
108. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. 2005. Self-propagating, molecular-level polymorphism in Alzheimer's β-Amyloid fibrils. Science 307:262-65
109. Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, et al. 2013. Structural and functional characterization of two α-synuclein strains. Nat. Commun. 4:2575
110. Westermark GT, Westermark P. 2010. Prion-like aggregates: infectious agents in human disease. Trends Mol. Med. 16:501-7
111. Westermark P. 2012. Subcutaneous adipose tissue biopsy for amyloid protein studies. MethodsMol. Biol. 849:363-711
112. Nilsson KP, Hammarstrom P, Ahlgren F, Herland A, Schnell EA, et al. 2006. Conjugated polyelectrolytes-conformation-sensitive optical probes for staining and characterization of amyloid deposits. ChemBioChem 7:1096-104
113. Nilsson KP, Ikenberg K, Aslund A, Fransson S, Konradsson P, et al. 2010. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am. J. Pathol. 176:563-74
114. Hawkins PN, Lavender JP, Pepys MB. 1990. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N. Engl. J. Med. 323:508-13
115. Hawkins PN, Vigushin DM, Kelsey CR, Gray RES, Hall MA, et al. 1993. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitativemonitoring ofAAamyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum. 36:842-51
116. Wall JS, Richey T, Stuckey AC, Donnell RL, Macy SD, et al. 2011. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. PNAS 108:13899-900
117. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, et al. 2013. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J. Nucl. Med. 54:213-20
118. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, et al. 2002. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N. Engl. J. Med. 346:1786-91
119. Sch onland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, et al. 2012. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119:488-93
120. Linke RP, Oos R, Wiegel NM, Nathrath WB. 2006. Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem. 108:197-208
121. Westermark P, Davey E, Lindbom K, Enqvist S. 2006. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem. 108:209-13
122. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. 2002. Electron and immunoelectron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 9:108-14
123. Murphy CL, Wang S, Williams T, Weiss DT, Solomon A. 2006. Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 412:48-62
124. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR III, Dogan A. 2009. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114:4957-59
125. Lavatelli F, Vrana JA. 2011. Proteomic typing of amyloid deposits in systemic amyloidosis. Amyloid 18:177-82
126. Waldenstrom H. 1928. On the formation and disappearance of amyloid in man. Acta Chir. Scand. 63:479-530
127. Tennent GA, Lovat LB, Pepys MB. 1995. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. PNAS 92:4299-303
128. O'Nuallain B, Wetzel R. 2002. Conformational Abs recognizing a generic amyloid fibril epitope. PNAS 99:1485-90
129. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-89
130. Solomon A, Weiss DT, Wall JS. 2003. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother. Radiopharm. 18:853-60
131. Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, et al. 2010. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 116:2241-44
132. Solomon A, Weiss DT, Wall JS. 2003. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin. Cancer Res. 9:3831S-38S
133. O'Nuallain B, Hrncic R, Wall JS, Weiss DT, Solomon A. 2006. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J. Immunol. 176:7071-78
134. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, et al. 2005. In vivo fragmentation of heparan sulfate by heparanase overexpression rendersmice resistant to amyloid protein A amyloidosis. PNAS 102:6473-77
135. Ancsin JB, Kisilevsky R. 1999. The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274:7172-81
136. Egashira M, Takase H, Yamamoto I, Tanaka M, Saito H. 2011. Identification of regions responsible for heparin-induced amyloidogenesis of human serum amyloid A using its fragment peptides. Arch. Biochem. Biophys. 511:101-6
137. Westermark GT, Engstr om U, Westermark P. 1992. The N-Terminal segment of protein AA determines its fibrillogenic property. Biochem. Biophys. Res. Commun. 182:27-33
138. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. 1995. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1:143-48
139. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, et al. 2007. Eprodisate for the treatment of renal disease in AA amyloidosis. N. Engl. J. Med. 356:2349-60
140. Kluve-Beckerman B, Hardwick J, Du L, Benson MD, Monia BP, et al. 2011. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid 18:136-46
141. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, et al. 2006. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33:609-18
142. Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, et al. 2010. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 17:43-49
143. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, et al. 2013. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369:819-29
144. McCutchen SL, Colon W, Kelly JW. 1993. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 16:12119-27
145. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. 1996. Inhibiting transthyretin amyloid fibril formation via protein stabilization. PNAS 93:15051-56
146. Sekijima Y, Dendle MA, Kelly JW. 2006. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13:236-49
147. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. 2012. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-Agencyapproved drug. J. Mol. Biol. 421:185-203
148. Palha JA, Ballinari D, Amboldi N, Cardoso I, Fernandes R, et al. 2000. 4-Iodo-4-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am. J. Pathol. 156:1919-25
149. Gertz MA, Lacy MQ, Dispenzieri A, Cheson BD, Barlogie B, et al. 2002. A multicenter phase II trial of 4-iodo-4-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 9:24-30
150. Cardoso I, Merlini G, Saraiva MJ. 2003. 4-Iodo-4-deoxydoxorubicin and tetracycline's disrupt transthyretin amyloid fibrils in vitro producing nontoxic species: screening for TTR fibril disrupters. FASEB J. 17:803-9
151. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, et al. 2014. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21:221-24